Stomach Neoplasm Clinical Trial
Official title:
A Phase II Trial of RAD001 (Everolimus) for 2nd Line Treatment After Failure of Fluoropyrimidine Plus Platinum Chemotherapy in Patients With Metastatic or Recurrent Gastric Cancer With pS6 Ser 240/4 Expression
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free
survival rate (primary end-point) and response rate, toxicity, overall survival and biomarker
assessment (secondary end-points) in patients with metastatic or recurrent gastric cancer
with pS6 Ser 240/4 expression.
Eligibility criteria include pathologically proven non-resectable adenocarcinoma of stomach
with measurable disease who failed previous first-line palliative chemotherapy including
fluoropyrimidine and platinum with high expression of pS6 Ser 240/4.
Oral RAD001 (everolimus) 10mg daily will be administered and the dose will be adjusted
according to the observed clinical toxicities. Treatment will be continued until disease
progression or patient's intolerability to the study drug.
A study requires 40 assessable subjects to decide whether the proportion of patients who are
free from progression at 4 months (16 weeks), P, is less than or equal to 0.1 or greater than
or equal to 0.25 with a target error rate of 0.05 and β of 0.2. If the number of responses is
7 or less, the hypothesis that P >= 0.250 is rejected with a target error rate of 0.200 and
an actual error rate of 0.182. If the investigators assume that drop-out rate is 10%, total
accrual patient will be 45.
Methodology: Prospective, non blinded, open label, single center phase II study
Criteria for evaluation: Assessment of response will be assessed radiologically according to
RECIST criteria after completion of the two cycles. Evaluation will be by physical
examination, chest X-ray, abdomen-pelvis CT scan Safety criteria: Physical examination, vital
signs, performance status, CBC, serum chemistry, NCI CTC V.3.0
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313700 -
Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer
|
N/A | |
Recruiting |
NCT05645198 -
The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy
|
Phase 4 | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT00935779 -
Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer
|
N/A | |
Completed |
NCT00144378 -
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
|
Phase 3 | |
Completed |
NCT00290966 -
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT03348150 -
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
|
Phase 3 | |
Not yet recruiting |
NCT06085677 -
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
|
||
Recruiting |
NCT02969122 -
Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor
|
N/A | |
Active, not recruiting |
NCT03760822 -
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
|
Phase 2 | |
Recruiting |
NCT00509964 -
Second-Line Irinotecan vs. ILF for AGC
|
Phase 2 | |
Completed |
NCT04889859 -
Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy
|
N/A | |
Completed |
NCT03071237 -
The Origin of Infrapyloric Artery
|
||
Recruiting |
NCT05184803 -
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
|
Phase 2 | |
Completed |
NCT05714878 -
Multimodal Prehabilitation for Resectable Gastric Cancer
|
N/A | |
Completed |
NCT00142038 -
Docetaxel and Capecitabine in Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04056260 -
ICG-NIR Guided Lymph Node Dissection in Gastric Cancer
|
N/A | |
Recruiting |
NCT03065257 -
Endoscopic Resection Multicenter Registry
|
N/A | |
Recruiting |
NCT04744649 -
Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
|
Phase 2 | |
Recruiting |
NCT05640609 -
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
|
Phase 1/Phase 2 |